Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease

Shailja C. Shah, Jason Glass, Gennaro Giustino, Joren R. Ten Hove, Daniel Castaneda, Joana Torres, Akash Kumar, Jordan Elman, Thomas A. Ullman, Steven H. Itzkowitz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: Statins have been postulated to lower the risk of colorectal neoplasia. No studies have examined any possible chemopreventive effect of statins in patients with inflammatory bowel disease (IBD) undergoing colorectal cancer (CRC) surveillance. This study examined the association of statin exposure with dysplasia and CRC in patients with IBD undergoing dysplasia surveillance colonoscopies. Methods: A cohort of patients with IBD undergoing colonoscopic surveillance for dysplasia and CRC at a single academic medical center were studied. The inclusion criteria were IBD involving the colon for ≥8 years (or any colitis duration if associated with primary sclerosing cholangitis [PSC]) and at least two colonoscopic surveillance exams. The exclusion criteria were CRC or high-grade dysplasia (HGD) prior to or at enrollment, prior colectomy, or limited (<30%) colonic disease. The primary outcome was the frequency of dysplasia and/or CRC in statin-exposed versus nonexposed patients. Results: A total of 642 patients met the inclusion criteria (57 statin-exposed and 585 nonexposed). The statin-exposed group had a longer IBD duration, longer follow-up period, and more colonoscopies but lower inflammatory scores, less frequent PSC and less use of thiopurines and biologics. There were no differences in low-grade dysplasia, HGD, or CRC development during the follow-up period between the statin-exposed and nonexposed groups (21.1%, 5.3%, 1.8% vs 19.2%, 2.9%, 2.9%, respectively). Propensity score analysis did not alter the overall findings. Conclusions: In IBD patients undergoing surveillance colonoscopies, statin use was not associated with reduced dysplasia or CRC rates. The role of statins as chemopreventive agents in IBD re-

Original languageEnglish (US)
Pages (from-to)54-61
Number of pages8
JournalGut and Liver
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inflammatory Bowel Diseases
Colorectal Neoplasms
Neoplasms
Colonoscopy
Sclerosing Cholangitis
Colonic Diseases
Propensity Score
Colectomy
Colitis
Biological Products
Colon

Keywords

  • Chemoprevention
  • Control
  • Epidemiology
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Neoplasia
  • Prevention

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Shah, S. C., Glass, J., Giustino, G., Ten Hove, J. R., Castaneda, D., Torres, J., ... Itzkowitz, S. H. (2019). Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease. Gut and Liver, 13(1), 54-61. https://doi.org/10.5009/gnl18178

Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease. / Shah, Shailja C.; Glass, Jason; Giustino, Gennaro; Ten Hove, Joren R.; Castaneda, Daniel; Torres, Joana; Kumar, Akash; Elman, Jordan; Ullman, Thomas A.; Itzkowitz, Steven H.

In: Gut and Liver, Vol. 13, No. 1, 01.01.2019, p. 54-61.

Research output: Contribution to journalArticle

Shah, SC, Glass, J, Giustino, G, Ten Hove, JR, Castaneda, D, Torres, J, Kumar, A, Elman, J, Ullman, TA & Itzkowitz, SH 2019, 'Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease', Gut and Liver, vol. 13, no. 1, pp. 54-61. https://doi.org/10.5009/gnl18178
Shah, Shailja C. ; Glass, Jason ; Giustino, Gennaro ; Ten Hove, Joren R. ; Castaneda, Daniel ; Torres, Joana ; Kumar, Akash ; Elman, Jordan ; Ullman, Thomas A. ; Itzkowitz, Steven H. / Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease. In: Gut and Liver. 2019 ; Vol. 13, No. 1. pp. 54-61.
@article{29ab3baf40b849de9e0acaa6de877771,
title = "Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease",
abstract = "Background/Aims: Statins have been postulated to lower the risk of colorectal neoplasia. No studies have examined any possible chemopreventive effect of statins in patients with inflammatory bowel disease (IBD) undergoing colorectal cancer (CRC) surveillance. This study examined the association of statin exposure with dysplasia and CRC in patients with IBD undergoing dysplasia surveillance colonoscopies. Methods: A cohort of patients with IBD undergoing colonoscopic surveillance for dysplasia and CRC at a single academic medical center were studied. The inclusion criteria were IBD involving the colon for ≥8 years (or any colitis duration if associated with primary sclerosing cholangitis [PSC]) and at least two colonoscopic surveillance exams. The exclusion criteria were CRC or high-grade dysplasia (HGD) prior to or at enrollment, prior colectomy, or limited (<30{\%}) colonic disease. The primary outcome was the frequency of dysplasia and/or CRC in statin-exposed versus nonexposed patients. Results: A total of 642 patients met the inclusion criteria (57 statin-exposed and 585 nonexposed). The statin-exposed group had a longer IBD duration, longer follow-up period, and more colonoscopies but lower inflammatory scores, less frequent PSC and less use of thiopurines and biologics. There were no differences in low-grade dysplasia, HGD, or CRC development during the follow-up period between the statin-exposed and nonexposed groups (21.1{\%}, 5.3{\%}, 1.8{\%} vs 19.2{\%}, 2.9{\%}, 2.9{\%}, respectively). Propensity score analysis did not alter the overall findings. Conclusions: In IBD patients undergoing surveillance colonoscopies, statin use was not associated with reduced dysplasia or CRC rates. The role of statins as chemopreventive agents in IBD re-",
keywords = "Chemoprevention, Control, Epidemiology, Hydroxymethylglutaryl-CoA reductase inhibitors, Neoplasia, Prevention",
author = "Shah, {Shailja C.} and Jason Glass and Gennaro Giustino and {Ten Hove}, {Joren R.} and Daniel Castaneda and Joana Torres and Akash Kumar and Jordan Elman and Ullman, {Thomas A.} and Itzkowitz, {Steven H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.5009/gnl18178",
language = "English (US)",
volume = "13",
pages = "54--61",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "1",

}

TY - JOUR

T1 - Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease

AU - Shah, Shailja C.

AU - Glass, Jason

AU - Giustino, Gennaro

AU - Ten Hove, Joren R.

AU - Castaneda, Daniel

AU - Torres, Joana

AU - Kumar, Akash

AU - Elman, Jordan

AU - Ullman, Thomas A.

AU - Itzkowitz, Steven H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aims: Statins have been postulated to lower the risk of colorectal neoplasia. No studies have examined any possible chemopreventive effect of statins in patients with inflammatory bowel disease (IBD) undergoing colorectal cancer (CRC) surveillance. This study examined the association of statin exposure with dysplasia and CRC in patients with IBD undergoing dysplasia surveillance colonoscopies. Methods: A cohort of patients with IBD undergoing colonoscopic surveillance for dysplasia and CRC at a single academic medical center were studied. The inclusion criteria were IBD involving the colon for ≥8 years (or any colitis duration if associated with primary sclerosing cholangitis [PSC]) and at least two colonoscopic surveillance exams. The exclusion criteria were CRC or high-grade dysplasia (HGD) prior to or at enrollment, prior colectomy, or limited (<30%) colonic disease. The primary outcome was the frequency of dysplasia and/or CRC in statin-exposed versus nonexposed patients. Results: A total of 642 patients met the inclusion criteria (57 statin-exposed and 585 nonexposed). The statin-exposed group had a longer IBD duration, longer follow-up period, and more colonoscopies but lower inflammatory scores, less frequent PSC and less use of thiopurines and biologics. There were no differences in low-grade dysplasia, HGD, or CRC development during the follow-up period between the statin-exposed and nonexposed groups (21.1%, 5.3%, 1.8% vs 19.2%, 2.9%, 2.9%, respectively). Propensity score analysis did not alter the overall findings. Conclusions: In IBD patients undergoing surveillance colonoscopies, statin use was not associated with reduced dysplasia or CRC rates. The role of statins as chemopreventive agents in IBD re-

AB - Background/Aims: Statins have been postulated to lower the risk of colorectal neoplasia. No studies have examined any possible chemopreventive effect of statins in patients with inflammatory bowel disease (IBD) undergoing colorectal cancer (CRC) surveillance. This study examined the association of statin exposure with dysplasia and CRC in patients with IBD undergoing dysplasia surveillance colonoscopies. Methods: A cohort of patients with IBD undergoing colonoscopic surveillance for dysplasia and CRC at a single academic medical center were studied. The inclusion criteria were IBD involving the colon for ≥8 years (or any colitis duration if associated with primary sclerosing cholangitis [PSC]) and at least two colonoscopic surveillance exams. The exclusion criteria were CRC or high-grade dysplasia (HGD) prior to or at enrollment, prior colectomy, or limited (<30%) colonic disease. The primary outcome was the frequency of dysplasia and/or CRC in statin-exposed versus nonexposed patients. Results: A total of 642 patients met the inclusion criteria (57 statin-exposed and 585 nonexposed). The statin-exposed group had a longer IBD duration, longer follow-up period, and more colonoscopies but lower inflammatory scores, less frequent PSC and less use of thiopurines and biologics. There were no differences in low-grade dysplasia, HGD, or CRC development during the follow-up period between the statin-exposed and nonexposed groups (21.1%, 5.3%, 1.8% vs 19.2%, 2.9%, 2.9%, respectively). Propensity score analysis did not alter the overall findings. Conclusions: In IBD patients undergoing surveillance colonoscopies, statin use was not associated with reduced dysplasia or CRC rates. The role of statins as chemopreventive agents in IBD re-

KW - Chemoprevention

KW - Control

KW - Epidemiology

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

KW - Neoplasia

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=85060138927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060138927&partnerID=8YFLogxK

U2 - 10.5009/gnl18178

DO - 10.5009/gnl18178

M3 - Article

VL - 13

SP - 54

EP - 61

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 1

ER -